全球瞩目的2025年欧洲肿瘤内科学会年会（ESMO Congress 2025）将于10月17日至21日在德国柏林盛大召开。7月25日，ESMO官网已公布除LBA之外的常规摘要题目及讲者信息。【肿瘤资讯】特此整理肿瘤免疫治疗领域入选Proffered Paper Session与Mini Oral Session的重磅临床研究，带您一睹前沿风采。
优选口头报告（Proffered Paper Session）
1511O - Locoregional bispecific CAR-T cells targeting CD44 and CD133 show safety and efficacy in recurrent high-grade glioma in a first-in-human investigator-initiated trial
中文标题：针对CD44和CD133的局部区域双特异性CAR-T细胞在复发性高级别胶质瘤中显示出安全性和疗效：一项首次人体研究者发起的试验
讲者：翟优（首都医科大学附属北京天坛医院）
1512O - NI-1801, a mesothelin x CD47 bispecific antibody: Safety and activity as single agent and in combination with pembrolizumab, in heavily pretreated (≥ 4 prior lines) mesothelin expressing platinum resistant epithelial ovarian cancer patients
中文标题：NI-1801，一种间皮素×CD47双特异性抗体：作为单药以及与帕博利珠单抗联合用于既往多线治疗（≥4线）的间皮素表达的铂耐药上皮性卵巢癌患者中的安全性和活性
讲者：Thibault De La Motte Rouge (Rennes, France)
1514O - First-in-human phase 1 study of TCR-T therapy targeting KRAS G12V in metastatic solid tumors
中文标题：首次人体1期研究：靶向KRAS G12V的TCR-T疗法用于转移性实体瘤
讲者：Xueli Bai (Hangzhou, China)
1513O - Long-term follow-up GDFATHER-01 trial: GDF-15 neutralization combined with nivolumab can enable deep, long-term remission in heavily pretreated, anti-PD1/-L1 relapsed/refractory non-squamous non-small cell lung cancer (NSCLC), urothelial cancer (UC) and hepatocellular cancer (HCC)
中文标题：GDFATHER-01试验长期随访：GDF-15中和联合纳武利尤单抗可使经多线治疗、抗PD-1/PD-L1复发/难治性非鳞状非小细胞肺癌（NSCLC）、尿路上皮癌（UC）和肝细胞癌（HCC）患者实现深度且长期的缓解
讲者：Ignacio Melero (Pamplona, Spain)
迷你口头报告（Mini oral session）
1515MO - Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma
中文标题：mRNA-4359联合帕博利珠单抗治疗免疫检查点抑制剂耐药/难治性（CPI-R/R）黑色素瘤的临床结果及PD-L1表达分析
讲者：David J. Pinato (London, United Kingdom)
1521MO - Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD-(L)1 therapy
中文标题：一项1期扩展队列研究结果：pH选择性抗VISTA抗体solnerstotug联合cemiplimab用于对既往PD-(L)1治疗耐药的晚期实体瘤患者
讲者：Kyriakos P. Papadopoulos (San Antonio, United States of America)
1522MO - A Phase 1 Study Of INCA33890, A PD-1/TGFβR2 Bispecific Antibody, For Advanced Solid Tumours
中文标题：INCA33890（一种PD-1/TGFβR2双特异性抗体）用于晚期实体瘤
讲者：Elena Garralda (Barcelona, Spain)
1517MO - Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
中文标题：Botensilimab和balstilimab的新兴生存平台效应：一项大型1b期晚期实体瘤试验的泛肿瘤数据
讲者：Michael Gordon (Scottsdale, United States of America)
1518MO - Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma (the ReCIPE-M1 study)
中文标题：通过血浆置换挽救黑色素瘤患者的癌症免疫治疗（ReCIPE-M1研究）
讲者：Jacob Orme (Rochester, United States of America)
1520MO - Phase I first-in-human study of a novel anti-CD137 switch antibody agonist STA551 (STA) as monotherapy and in combination with atezolizumab (atezo) in patients (pts) with advanced solid tumors
中文标题：一项1期首次人体研究：新型抗CD137开关抗体激动剂STA551（STA）单药治疗以及与阿替利珠单抗（atezo）联合用于晚期实体瘤患者（pts）
讲者：Diogo Silva (Senhora da Hora, Portugal)
1516MO - EVX-01, a personalized cancer vaccine, induces potent T-cell responses and durable disease control in advanced melanoma: 2-year follow-up
中文标题：EVX-01，一种个性化癌症疫苗，在晚期黑色素瘤中诱导强烈的T细胞反应和持久的疾病控制：2年随访
讲者：Muhammad A. Khattak (Perth, Australia)
1519MO - Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Progress to date
中文标题：系统性STING激动剂BI 1703880联合ezabenlimab用于晚期实体瘤患者（pts）的Ia期研究结果：迄今为止的进展
讲者：Eileen E. Parkes (Oxford, United Kingdom)
排版编辑：肿瘤资讯-Bear
苏公网安备32059002004080号
